Current Updates on Antimicrobial Resistance in Pediatric Patients, 2nd Edition

Dear Colleagues,

Antimicrobial resistance (AMR) is currently one of the most important threats to public health worldwide and should be considered a top priority by all public health professionals and institutions.

The prevalence of multidrug-resistant organisms (MDROs) is significantly increasing and is associated with significant morbidity and mortality in affected patients. MDR bacteria are more resistant to treatment and are associated with more severe and prolonged disease, leading to longer hospitalization, with a 20% increase in the length of stay and deprivation outcomes, increasing mortality by up to 40% for hospital-acquired MDR infections.

Children are known to be the main beneficiaries of antimicrobial drugs compared to any other form of medication, as they are frequent subjects of infections of various etiologies, from the most common urinary tract infections to the less common meningitis. The most important cause of modern antibiotic resistance is the inappropriate use of antibiotics.

An insufficient knowledge of the pathogens associated with different infections, along with the pharmacokinetic and pharmacodynamic properties of specific classes of antibiotics, underlies bacterial resistance. These characteristics have a significant impact on the drug selection process, on the correct dosage and on the duration of treatment.

In addition, antibiotics are still frequently prescribed for misdiagnosed conditions such as viral infections, especially in ambulatory care.

This Special Issue plans to provide an overview of the most recent advances in the field of antimicrobial resistance in pediatric patients.

Potential topics include, but are not limited to, the following:

• Antimicrobial resistance;
• Inappropriate antibiotic use in pediatrics;
• Public health;
• Adverse effects of antibiotics;
• Multidrug-resistant bacteria;
• Future perspectives on antimicrobial resistance;
• Role of antimicrobial resistance in pediatric patients.

Dr. Stefania Vergnano
Dr. Corina Maria Vasile
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antimicrobial resistance
• inappropriate antibiotic use in pediatrics
• public health
• adverse effects of antibiotics
• multidrug-resistant bacteria
• future perspectives on antimicrobial resistance
• role of antimicrobial resistance in pediatric patients

• Current Updates in Antimicrobial Resistance in Pediatric Patients in Antibiotics (7 articles)